المؤلفون: National Cancer Institute (NCI), Agenus Inc., American Brain Tumor Association

المساهمون: Orin Bloch, MD, Principal Investigator

المصدر: Crane CA, Han SJ, Ahn B, Oehlke J, Kett V, Fedoroff A, ButowskN, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT. dual patnt-spec muny agast hh-grade glma after vaccatn wh autologous tumor dered peptes bound to the 96 KD chaperone prote. Cl Cancer Res. 2013 Jan 1;19(1):205-14. do 10.1158/1078-0432.CCR-11-3358. Epub 2012 Aug 7.
Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan;16(2):274-9. doi: 10.1093/neuonc/not203. Epub 2013 Dec 12.
Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00293423Test

المؤلفون: Agenus Inc.

المساهمون: Orin Bloch, MD, Principal Investigator

المصدر: Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O'Rourke DM, D'Ambrosio A, Bruce JN, Parsa AT. Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Clin Cancer Res. 2017 Jul 15;23(14):3575-3584. doi: 10.1158/1078-0432.CCR-16-1369. Epub 2017 Feb 13.
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00905060Test